J
Joachim Drevs
Researcher at University of Freiburg
Publications - 64
Citations - 5066
Joachim Drevs is an academic researcher from University of Freiburg. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor. The author has an hindex of 32, co-authored 64 publications receiving 4918 citations. Previous affiliations of Joachim Drevs include Ruhr University Bochum.
Papers
More filters
Journal Article
PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
J.M. Wood,G. Bold,Elisabeth Buchdunger,Robert Cozens,Stefano Ferrari,J. Frei,Francesco Hofmann,J. Mestan,Helmut Mett,Terence O'reilly,E Persohn,Johannes Rösel,Christian Schnell,David R. Stover,Andreas Theuer,H Towbin,F Wenger,Kathie Woods-Cook,Andreas Menrad,Gerhard Siemeister,Michael Schirner,Thierauch Kh,Martin R. Schneider,Joachim Drevs,Georg Martiny-Baron,Frank Totzke +25 more
TL;DR: A novel compound with therapeutic potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role, PTK787/ZK 222584 is very well tolerated and does not impair wound healing.
Journal ArticleDOI
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
Bruno Morgan,Anne L. Thomas,Joachim Drevs,Juergen Hennig,Martin Büchert,Asvina Jivan,Mark A. Horsfield,K. Mross,H. A. Ball,Lucy Lee,William Mietlowski,Stefan Fuxius,Clemens Unger,Kenneth J. O'Byrne,Andrew Henry,Graham R. Cherryman,Dirk Laurent,Margaret Dugan,Dieter Marmé,William P. Steward +19 more
TL;DR: In this article, the authors evaluated the pharmacodynamic effects of PTK/ZK by assessing changes in contrastenhancement parameters of metastatic liver lesions using dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) in patients with advanced colorectal cancer treated in two ongoing, dose-escalating phase I studies.
Journal Article
Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model
Joachim Drevs,Inga Hofmann,Harald Hugenschmidt,Christine Wittig,Helmut Madjar,Marianne Müller,Jeanette Marjorie Wood,Georg Martiny-Baron,Clemens Unger,Dieter Marmé +9 more
TL;DR: Results demonstrate that PTK787/ZK 222584 is a potent inhibitor of tumor growth, metastases formation, and tumor vascularization in murine renal cell carcinoma and demonstrate that color Doppler imaging ultrasound can be used to measure blood flow to a tumor and that flow correlates with vessel density.
Journal ArticleDOI
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
Joachim Drevs,Patrizia Siegert,Michael Medinger,Klaus Mross,Ralph Strecker,Ute Zirrgiebel,Jan Harder,Hubert E. Blum,Jane Robertson,Juliane M. Jürgensmeier,Thomas A. Puchalski,Helen Young,Owain Saunders,Clemens Unger +13 more
TL;DR: Once-daily oral AZD2171 at doses of 45 mg or less was generally well tolerated and was associated with encouraging antitumor activity in patients with a broad range of advanced solid tumors.
Journal Article
PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging
Joachim Drevs,Ralph Müller-Driver,Christine Wittig,Stefan Fuxius,Norbert Esser,Harald Hugenschmidt,Moritz A. Konerding,Peter R. Allegrini,Jeanette Marjorie Wood,Jürgen Hennig,Clemens Unger,Dieter Marmé +11 more
TL;DR: It is concluded that the treatment with PTK787/ZK 222584 primarily reduces the number of tumor microvessels, accompanied by a hemodynamic dilation of the remaining vessels, which could influence the result of dyMRI and cause no change in extravasation or even an increase in partial tumor blood volume.